Article
Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Clinica chimica acta; international journal of clinical chemistry - 21 Oct 2013
Netzel Brian C, Grebe Stefan K G
Abstract excerpt
BACKGROUND: KRAS codons 12 and 13 mutations are commonly used to identify colorectal carcinoma (CRC) patients who are unlikely to benefit from anti-EGFR therapy. However, humans have four different homologous RAS proteins and no routine screening is performed for the other mutation sites. Non-screened mutations may still be present in a significant subset of patients without KRAS codon 12 and 13 mutations....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.